Need Help?

Comparison with genomic measurement

Heatrich-BS was performed on 5 healthy volunteers and 15 CRC patient cell-free DNA. The Heatrich-BS predicted tumor fractions were compared with tumor burden values obtained by genomic methods such as targeted amplicon sequencing and low pass sequencing.

Request Access

Policy for processing data access request

Policy for processing data access requests This policy describes how the NUS cfDNA Data Access Committee (DAC) will process requests for datasets stored in the European Genome-phenome Archive (EGA), when those datasets are made available by manuscripts that specifically reference this policy. Purpose 1. To ensure that applicants are qualified investigators, affiliated with an academic, non- profit, or government research organization. 2. To ensure that users of the data agree to comply with applicable laws, including requirements as outlined in any governing consent and appropriate ethical approvals, along with any restrictions for the data in question. General principles Introduction The DAC will consider applications for access to datasets stored in the EGA when authorized to do so in accordance with this policy. Access to data will be granted to qualified researchers for appropriate use. A qualified researcher refers to a scientist who is employed, or legitimately affiliated with an academic, non-profit, or government research organization. Access to data will be granted to researchers for appropriate use and will be governed by the provisions and terms contained in the Data Access Agreement and consistent with an informed consent (if applicable). The DAC is concerned only with access to the data stored within the EGA with this DAC as the designated data access committee. Access is conditional upon availability of data and a signed agreement governing issues related to publication, data use, data storage, data disposal, ethical approval, and confidentiality. Application procedure To request access to data from the EGA, you will be asked to complete a basic application form and to agree to the terms and conditions laid out in the Data Access Agreement (DAA). The DAA must be signed by both a representative with institutional authority to sign on behalf of your organization, and the principal investigator responsible for the research project. You will also be requested to list personnel who will be granted access to the data for the purposes of the research project. If your application is successful, you will be asked to designate a “registered user”, under the authority of the principal investigator, who will be issued with a username and password by the EGA to enable access to the database. The DAC will consider applications that include named collaborators, but each institution must sign a separate DAA. Should you wish to share the data with additional collaborators not previously approved, they must make a separate application for access to the data. You agree to use the data only for the approved purpose and project described in your application; use of the data for a new purpose or new or expanded project will require a new application and approval. Assessment criteria Each application will be assessed to determine if: ● it has been submitted by a qualified researcher or researchers, embedded in a recognized research institution that can provide institutional responsibility for appropriate research governance ● the project described constitutes “biomedical research” in the context of the consent process, and is likely to be understood as such by the sample donors ● it breaches any of the ethical permissions or restrictions in the consent forms for any component cohort or collection The DAC will use these practices in its assessment: ● The DAC explicitly does NOT attempt to peer review the scientific quality of proposals. However, it does ask for a brief summary of the research to be undertaken, in order to judge whether it falls within the scope of the consents. Reporting The DAC may periodically report publicly on the requests received and their disposition, including reasons for access refusal. Acknowledgments Purpose adapted from the Blueprint Data Access Committee Terms of Reference. General principles adapted from the Blueprint Data Access Committee General Principles.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00006143482 1649675161970 261.2 MB
EGAF00006143483 1649675161970 285.6 MB
EGAF00006143492 1649675161970 129.2 MB
EGAF00006143493 1649675291285 142.8 MB
EGAF00006143512 1649675344355 263.0 MB
EGAF00006143513 1649675161970 283.9 MB
EGAF00006143514 1649675221269 417.9 MB
EGAF00006143515 1649675221269 479.2 MB
EGAF00006143524 1649675102257 84.2 MB
EGAF00006143525 1649675161970 94.6 MB
EGAF00006143526 1649675291285 591.2 MB
EGAF00006143527 1649675291285 665.6 MB
EGAF00006143530 1649675291285 530.2 MB
EGAF00006143531 1649675221269 605.0 MB
EGAF00006143562 1649675102257 174.4 MB
EGAF00006143563 1649675221269 193.8 MB
EGAF00006143564 1649675102257 537.5 MB
EGAF00006143565 1649675291285 579.1 MB
EGAF00006143568 1649675161970 33.2 MB
EGAF00006143569 1649675161970 36.0 MB
EGAF00006143586 1649675161970 210.6 MB
EGAF00006143587 1649675221269 228.1 MB
EGAF00006143590 1649675221269 113.5 MB
EGAF00006143591 1649675161970 123.6 MB
EGAF00006143594 1649675221269 84.3 MB
EGAF00006143595 1649675221269 91.5 MB
EGAF00006143638 1649675291285 403.0 MB
EGAF00006143639 1649675291285 448.3 MB
EGAF00006143646 1649675221269 185.0 MB
EGAF00006143647 1649675291285 179.9 MB
EGAF00006143648 1649675161970 151.8 MB
EGAF00006143649 1649675102257 149.1 MB
EGAF00006143650 1649675291285 704.5 MB
EGAF00006143651 1649675344355 669.3 MB
EGAF00006143658 1649675102257 143.3 MB
EGAF00006143659 1649675102257 155.4 MB
EGAF00006143660 1649675161970 284.2 MB
EGAF00006143661 1649675344355 334.7 MB
EGAF00006143662 1649675161970 350.9 MB
EGAF00006143663 1649675291285 401.4 MB
40 Files (11.8 GB)